Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fidia Farmaceutici SPA

www.fidiapharma.com

Latest From Fidia Farmaceutici SPA

Global Device Approvals Snapshot For March 26–April 1, 2019

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, FDA approved Channel Medysystems’ Cerene cryotherapy for endometrial ablation and Fidia Pharma’s Triluron hyaluronic acid for knee pain.

Commercial Approvals

Pipeline Watch: Phase III Progress With Eylea, Tecentriq And HTX-011

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

New Injectables For Knee OA Fuel US Joint Fluid Market

Although several factors have recently slowed growth in the US market for joint fluid replacement, it remains large and vastly underpenetrated with an estimated 15.8 million knee osteoarthritis patients who are hoping to delay the need for a total knee arthroplasty. With a growing number of products in the pipeline and increasing adoption of new single-injection products, the US joint fluid market is projected to increase from approximately $924.4 million in 2015 to more than $1.07 billion by 2019, a CAGR of 4%.

Medical Device Innovation

Knee OA: Growing Demand For Nonsurgical Options

The knee replacement market is posting flat growth across the board as more patients seek nonsurgical options to manage their pain. Although such treatments typically last only a few months, many patients willingly accept the durability tradeoff to avoid the cost and downtime associated with surgery.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Italy
  • Parent & Subsidiaries
  • Fidia Farmaceutici SPA
  • Senior Management
  • Ennio Arengi, Pres. & CEO
    Marilena Bianco, CFO
    Giuseppe Giorgini, Mktg. Dir.
  • Contact Info
  • Fidia Farmaceutici SPA
    Phone: (39) 498 232111
    Via Ponte della Fabbrica 3/A
    Abano Terme, I-35031
    Italy
Advertisement
Advertisement
UsernamePublicRestriction

Register